| Established and emerging biological activity markers of inflammatory bowel disease OH Nielsen, B Vainer, SM Madsen, JB Seidelin, NHH Heegaard The American Journal of Gastroenterology 95 (2), 359-367, 2000 | 299* | 2000 |
| IL-33 is upregulated in colonocytes of ulcerative colitis JB Seidelin, JT Bjerrum, M Coskun, B Widjaya, B Vainer, OH Nielsen Immunology Letters 128 (1), 80-85, 2010 | 179 | 2010 |
| MAP kinases in inflammatory bowel disease M Coskun, J Olsen, JB Seidelin, OH Nielsen Clinica Chimica Acta 412 (7), 513-520, 2011 | 176 | 2011 |
| ATG16L1: A multifunctional susceptibility factor in Crohn disease M Salem, M Ammitzboell, K Nys, JB Seidelin, OH Nielsen Autophagy 11 (4), 585-594, 2015 | 167 | 2015 |
| Diagnosis of ulcerative colitis before onset of inflammation by multivariate modeling of genome‐wide gene expression data J Olsen, TA Gerds, JB Seidelin, C Csillag, JT Bjerrum, JT Troelsen, ... Inflammatory Bowel Diseases 15 (7), 1032-1038, 2009 | 123 | 2009 |
| Inhibitors of apoptosis (IAPs) regulate intestinal immunity and inflammatory bowel disease (IBD) inflammation J Pedersen, EC LaCasse, JB Seidelin, M Coskun, OH Nielsen Trends in Molecular Medicine 20 (11), 652-665, 2014 | 117 | 2014 |
| miR-20b, miR-98, miR-125b-1*, and let-7e* as new potential diagnostic biomarkers in ulcerative colitis M Coskun, JT Bjerrum, JB Seidelin, JT Troelsen, J Olsen, OH Nielsen World journal of gastroenterology: WJG 19 (27), 4289, 2013 | 117 | 2013 |
| Micro-RNA profile in inflammatory bowel disease M Coskun, JT Bjerrum, JB Seidelin, OH Nielsen World J Gastroenterol 15 (45), 5751-5753, 2009 | 115* | 2009 |
| Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study C Steenholdt, A Molazahi, MA Ainsworth, J Brynskov, OØ Thomsen, ... Scandinavian Journal of Gastroenterology 47 (5), 518-527, 2012 | 111 | 2012 |
| Pathogenesis and biomarkers of carcinogenesis in ulcerative colitis S Thorsteinsdottir, T Gudjonsson, OH Nielsen, B Vainer, JB Seidelin Nature reviews Gastroenterology & hepatology 8 (7), 395-404, 2011 | 104 | 2011 |
| Asymptomatic carriers contribute to nosocomial Clostridium difficile infection: a cohort study of 4508 patients T Blixt, KO Gradel, C Homann, JB Seidelin, K Schønning, A Lester, ... Gastroenterology 152 (5), 1031-1041. e2, 2017 | 102 | 2017 |
| Characterization of the enhancer and promoter landscape of inflammatory bowel disease from human colon biopsies M Boyd, M Thodberg, M Vitezic, J Bornholdt, K Vitting-Seerup, Y Chen, ... Nature communications 9 (1), 1661, 2018 | 94 | 2018 |
| Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised … L Peyrin-Biroulet, A Hart, P Bossuyt, M Long, M Allez, P Juillerat, ... The lancet Gastroenterology & hepatology 7 (2), 128-140, 2022 | 85 | 2022 |
| Culturing human intestinal stem cells for regenerative applications in the treatment of inflammatory bowel disease FEO Holmberg, JB Seidelin, X Yin, BE Mead, Z Tong, Y Li, JM Karp, ... EMBO molecular medicine 9 (5), 558-570, 2017 | 81 | 2017 |
| Prevalence and outcomes of COVID-19 among patients with inflammatory bowel disease—a Danish prospective population-based cohort study M Attauabi, A Poulsen, K Theede, N Pedersen, L Larsen, T Jess, ... Journal of Crohn's and Colitis 15 (4), 540-550, 2021 | 80 | 2021 |
| Soluble L-selectin levels predict survival in sepsis JB Seidelin, OH Nielsen, J Strøm Intensive Care Medicine 28 (11), 1613-1618, 2002 | 77 | 2002 |
| COX-2–PGE2 signaling impairs intestinal epithelial regeneration and associates with TNF inhibitor responsiveness in ulcerative colitis Y Li, C Soendergaard, FH Bergenheim, DM Aronoff, G Milne, LB Riis, ... EBioMedicine 36, 497-507, 2018 | 75 | 2018 |
| Defining transabdominal intestinal ultrasound treatment response and remission in inflammatory bowel disease: systematic review and expert consensus statement JFKF Ilvemark, T Hansen, TM Goodsall, JB Seidelin, H Al-Farhan, ... Journal of Crohn's and Colitis 16 (4), 554-580, 2022 | 64 | 2022 |
| A role for interleukin-33 in TH2-polarized intestinal inflammation JB Seidelin, G Rogler, OH Nielsen Mucosal Immunology 4 (5), 496-502, 2011 | 61 | 2011 |
| Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study S Vermeire, PL Lakatos, T Ritter, S Hanauer, B Bressler, R Khanna, ... The Lancet Gastroenterology & Hepatology 7 (1), 28-37, 2022 | 56 | 2022 |
Ole Haagen NielsenProfessor of Medicine, Dept. of Gastroenterology, Herlev Hospital, University of Copenhagen, Denmark在 dadlnet.dk 的电子邮件经过验证
